In this study we report the highest resolution proteomics analysis performed in dystrophic muscle to date. The use of two mouse models of Duchenne muscular dystrophy, at three different ages, has enabled the identification of mutation-independent protein signatures associated with dystrophic muscle, and the progression of disease pathology. Display omitted Highlights•Proteomics analysis was performed in two murine models of Duchenne muscular dystrophy (mdx and mdx52) at three ages (8, 16 and 80 weeks) and compared with wild-type controls.•High-resolution isoelectric focusing liquid chromatography-tandem mass spectrometry enabled the quantification of 4974 proteins in all samples.•This study has revealed protein signatures of dystrophin deficiency and the progression of dystrophic pathology.•In contrast, the proteomes of the mdx and mdx52 mice were highly similar.•Pathway analysis revealed crosstalk between inflammatory, metabolic and muscle growth processes in dystrophic muscle. The absence of the dystrophin protein in Duchenne muscular dystrophy (DMD) results in myofiber fragility and a plethora of downstream secondary pathologies. Although a variety of experimental therapies are in development, achieving effective treatments for DMD remains exceptionally challenging, not least because the pathological consequences of dystrophin loss are incompletely understood. Here we have performed proteome profiling in tibialis anterior muscles from two murine DMD models (mdx and mdx52) at three ages (8, 16, and 80 weeks of age), all n = 3. High-resolution isoelectric focusing liquid chromatography-tandem MS (HiRIEF-LC–MS/MS) was used to quantify the expression of 4974 proteins across all 27 samples. The two dystrophic models were found to be highly similar, whereas multiple proteins were differentially expressed relative to WT (C57BL/6) controls at each age. Furthermore, 1795 proteins were differentially expressed when samples were pooled across ages and dystrophic strains. These included numerous proteins associated with the extracellular matrix and muscle function that have not been reported previously. Pathway analysis revealed multiple perturbed pathways and predicted upstream regulators, which together are indicative of cross-talk between inflammatory, metabolic, and muscle growth pathways (e.g. TNF, INFγ, NF-κB, SIRT1, AMPK, PGC-1α, PPARs, ILK, and AKT/PI3K). Upregulation of CAV3, MVP and PAK1 protein expression was validated in dystrophic muscle by Western blot. Furthermore, MVP was upregulated during, but not required for, the differentiation of C2C12 myoblasts suggesting that this protein may affect muscle regeneration. This study provides novel insights into mutation-independent proteomic signatures characteristic of the dystrophic phenotype and its progression with aging.